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JDS–chromium–insulin (CRI)-003 is a novel form of insulin that has been directly conju-
gated with chromium (Cr) instead of zinc. Our hypothesis was that CRI enhances insulin’s
effects by altering insulin-degrading enzyme (IDE) and proteasome enzymes. To test this
hypothesis, we measured hepatic IDE content and proteasome parameters in a diabetic
animal model. Male KKAy mice were randomly divided into three groups (n=8/group);
Sham (saline), human regular insulin (Reg-In), and chromium conjugated human insulin
(CRI), respectively. Interventions were initiated at doses of 2 U insulin/kg body weight daily
for 8-weeks. Plasma glucose and insulin were measured. Hepatic IDE, proteasome, and
insulin signaling proteins were determined by western blotting. Insulin tolerance tests at
week 7 showed that both insulin treatments significantly reduced glucose concentrations
and increased insulin levels compared with the Sham group, CRI significantly reduced glu-
cose at 4 and 6 h relative to Reg-In (P <0.05), suggesting the effects of CRI on reducing
glucose last longer than Reg-In. CRI treatment significantly increased hepatic IRS-1 and
Akt1 and reduced IDE, 20S as well as 19S protein abundance (P <0.01, P <0.05, and
P <0.001, respectively), but Reg-In only significantly increased Akt1 (P <0.05). Similar
results were also observed in Reg-In- and CRI-treated HepG2 cells. This study, for the first
time, demonstrates that CRI reduces plasma insulin clearance by inhibition of hepatic IDE
protein expression and enhances insulin signaling as well as prevents degradation of IRS-1
and IRS-2 by suppressing ubiquitin-proteasome pathway in diabetic mice.
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INTRODUCTION
Chromium is an essential mineral that appears to have beneficial
effects in the regulation of insulin action and in the improvement
of carbohydrate and lipid metabolism (1, 2). Studies show that
people with type 2 diabetes have lower blood levels of chromium
than those without the disease (3). Insulin resistance is the com-
mon denominator in a cluster of cardiovascular disease risk factors
(4). Chromium picolinate (CrPic) has been shown to reduce
insulin resistance and to help reduce the risk of cardiovascu-
lar disease and type 2 diabetes (5). It was observed in obese
KK/HlJ diabetic mouse model that the improvement in insulin
signaling by chromium was associated with the decreased IRS-
1 Ser307 phosphorylation, JNK activity, and pro-inflammatory
cytokine production (6). Our previous study showed that CrPic
supplementation significantly enhances insulin signaling in mus-
cle of obese JCR:LA-cp rats when compared with control rats (7).
Chromium dinicocysteinate (CDNC), a complex of chromium
and l-cysteine, has been noted to beneficial in lowering insulin
resistance by reducing blood levels of TNF-α, insulin,and oxidative
Abbreviations: IDE, insulin-degrading enzyme; IRS-1, insulin receptor substrate 1;
UPS, ubiquitin-proteasome system.
stress in type 2 diabetic subjects in a randomized, double-blind,
placebo-controlled study (8). Clinical studies showed that the ben-
eficial effects of CrPic supplementation included reduced blood
glucose, insulin, cholesterol, and triglyceride levels and reduced
requirements for hypoglycemic medication (9). However, these
chromium supplementations (CDNC and CrPic) are only oral
ones.
JDS–chromium–insulin (CRI)-003 is a novel form of insulin
that has been directly conjugated with chromium (Cr) instead of
zinc. CRI contains approximately 0.82% chromium by weight,
which corresponds to approximately six chromium atoms per
insulin hexamer unit. JDS-CRI-003 is a highly purified form of
the chromium–insulin complex. Earlier studies have evaluated the
activity of a crude mixture of the chromium–insulin complex, but
this is the first study to evaluate the effects of the purified version
of CRI.
Insulin clearance plays a major role in glucose homeostasis and
insulin sensitivity in physiological and/or pathological conditions,
such as obesity-induced type 2 diabetes as well as diet-induced
obesity (10). Insulin clearance mostly depends on degradation by
liver via the insulin-degrading enzyme (IDE) (11). IDE is a highly
conserved zinc metallopeptidase that is ubiquitously distributed
in human tissues and particularly abundant in the brain, liver,
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and muscles (12). IDE activity has been historically associated
with insulin and β-amyloid catabolism. However, over the last
decade, several experimental findings have established that IDE
is also involved in a wide variety of physiopathological processes,
including ubiquitin clearance and varicella zoster virus infection
(13). IDE is believed to act as a junction point of type 2 dia-
betes and Alzheimer’s disease (AD) (14). The preferential affinity
of this enzyme for insulin results in insulin-mediated inhibition
of the degradation of other peptides such as beta-amyloid. IDE
localizes primarily to the cytoplasm but in some cell types local-
izes to the extracellular space, cell membrane, peroxisome, and
mitochondrion (15, 16). Recent study demonstrated that insulin
significantly increased the mRNA levels of insulin-like growth fac-
tor 1 and insulin-like growth factor 1 receptor. These impacts could
be enhanced by the addition of chromium, especially chromium
chelated with small peptides (CrSP). The mRNA levels of ubiq-
uitin were significantly reduced when cells were cultured with
chromium or/and insulin (17).
Our hypothesis is that CRI may be better than regular insulin
(Reg-In) in reducing plasma glucose and insulin clearance by
inhibiting IDE protein expression in the liver. On the other hand,
CRI may enhance insulin signaling when compared with Reg-In in
diabetic animal model by altering ubiquitin-proteasome activity,
it has been reported that prolong insulin treatment in adipocytes
induces a decrease in IRS-1 due to an enhancement of IRS-1
degradation mediated by the proteasome pathway (18). To test
this hypothesis, we measured hepatic IDE, 19S, 20S proteasome
and insulin signaling proteins in KKAy diabetic mice treated with
CRI, Reg-In, and vehicle saline (Sham). In vitro experiments also




Insulin stock solutions were made at insulin concentrations of
200 U/ml using the powders of Reg-In (human insulin, Sigma
lot no. 12G374G) and CRI (chromium-bound human insulin,
lot no. 112017) provided by JDS Therapeutics, LLC. (Pur-
chase, NY, USA). CRI contains 0.82% chromium (per weight of
insulin). The identical concentrations of these two insulin solu-
tions were confirmed by measuring insulin after 1:1000 dilutions
with PBS using a human insulin enzyme-linked immunosor-
bent assay (ELISA) kit (Millipore, Billerica, MA, USA). The
results showed that insulin concentrations were 194± 6.7µU/ml
in Reg-In and 195.3± 3.8µU/ml in CRI solutions, respectively
[mean± standard error of the mean (SEM), n= 4,P =NS, Figure
S1 in Supplementary Material].
ANIMAL STUDY
All animal experiments were performed according to a protocol
approved by the Institutional Animal Care and Use Committee of
Pennington Biomedical Research Center. To determine the effects
of these two types of insulin on lowering blood glucose and insulin
levels in a time course after injection of insulin in KKAy mice.
Twenty-four male 5-week-old KKAy mice were obtained from the
Jackson Laboratory (Bar Harbor, ME, USA). After arrival, the ani-
mals were housed in two mice/cage with ad libitum access to rodent
chow and water for a 2-week acclimation period under specific
pathogen-free conditions and 12-h light–dark cycle. Then, these
mice were be randomly divided into three groups (n= 8/group);
Sham, Reg-In treated, and CRI groups, respectively. All treated
groups were injected insulin at dose of 2 U/kg body weight daily,
and Sham group was injected the same volume of saline for 8 weeks
as insulin groups. Food intake and body weight were recorded
every week.
BLOOD CHEMISTRY, LIPIDS, AND HORMONE ANALYSIS
Pharmaceutical kinetics dynamics study of CRI was performed
at week 7 by intramuscular insulin injection in KKAy mice after
2 h fasting. Blood samples were collected at 0, 0.5, 1, 2, 4, and
6 h from tail bleeding (10µl at each time point) into microcen-
trifuge tubes containing 10µl of EDTA solution, before and after
injection of insulin (Sham animals were injected saline, and the
other two groups were injected Reg-In or CRI at dose of 2 U/kg
body weight, respectively). Plasma insulin levels were determined
by human ELISA kits from Millipore (Billerica, MA, USA) and
plasma glucose concentrations were measured by a colorimetric
hexokinase glucose assay (Sigma Diagnostics, St Louis, MO, USA).
Plasma cholesterol and triglyceride concentrations were measured
by a triglyceride assay kit (Eagle Diagnostics, DeSoto, TX, USA)
and a cholesterol quantitation kit (BioVision, Milpitas, CA, USA),
respectively.
WESTERN BLOTTING ANALYSIS
Liver lysates were prepared by homogenization in buffer A (25 mM
HEPES, pH 7.4, 1% nonidet P-40 (NP-40), 137 mM NaCl, 1 mM
PMSF, 10µg/ml aprotinin, 1µg/ml pepstatin, 5µg/ml leupeptin)
using a PRO 200 homogenizer (PRO scientific, Oxford, CT, USA).
The samples were centrifuged at 14,000× g for 20 min at 4°C
and protein concentrations of the supernatants were determined
by Bio-Rad protein assay kit (Bio-Rad laboratories, Inc., Her-
cules, CA, USA). Supernatants (50µg) were resolved by 8 or 12%
SDS-PAGE and subjected to immunoblotting. The protein abun-
dance was detected with antibodies against IRS-1 p(Tyr612), IRS-1,
IRS-2, IR β, PI 3K, Akt2 p(Ser474), 20S proteasome catalytic core
(CP) β2i, Akt2 (Millipore, Temecula, CA, USA), IDE (Covance,
Princeton, NJ, USA), 19S proteasome base anti-S5A/Rpn10 (Cal-
biochem, Gibbstown, NJ, USA), and β-actin (Thermo Scientific,
Pittsburgh, PA, USA) using a Western Lightning Chemilumines-
cence Reagent Plus kit (PerkinElmer Life Science, Boston, MA,
USA), and quantified via densitometer. All the proteins were
normalized to β-actin.
STATISTICAL ANALYSIS
Data were expressed as mean± SEM. Comparisons of groups were
implemented by unpaired t -test (two-sided) or ANOVA. AP-value
<0.05 was considered statistically significant.
RESULTS
Body weights, fasting plasma glucose, and insulin levels were iden-
tical in all animal groups at the beginning of study. After 8-week
intervention, the body weights in Reg-In and CRI groups were
slightly lower than Sham group, but there were no significant dif-
ferences between these groups. Food intake was slightly lower in
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FIGURE 1 | Body weight, food intake and plasma lipids
concentrations in Sham, Reg-In, and CRI treated mice. Body weight
and food intake of mice were recorded weekly. Fasting plasma lipid
concentrations were measured at week 7. (A) Showed body weights in
the mice; (B) is food intake in these mice; (C) showed plasma
triglyceride concentrations; (D) is plasma cholesterol levels in KKAy mice.
Mean±SEM (n= 8/group). ***P <0.001, CRI vs. Sham, ##P <0.01, CRI
vs. Reg-In.
Sham animals than in Reg-In and CRI groups, and there were no
significant differences in these groups as well (Figures 1A,B). Fast-
ing plasma triglyceride concentrations were slightly lower in the
Reg-In group than Sham group (P =NS), but were significantly
lower in CRI animals than in Sham and Reg-In animals (P < 0.001
and P < 0.01, respectively, Figure 1C). CRI and Reg-In treatment
slightly reduced plasma cholesterol levels when compared with
Sham mice (P =NS, Figure 1D).
The data of pharmaceutical kinetic dynamics study showed
that plasma glucose levels at baseline (0 time) were significantly
lower in the Reg-In and the CRI groups than in the Sham group
(P < 0.01). After insulin injection, the maximal effects of low-
ering glucose for both insulin solutions occur at 60 min. CRI
significantly reduced glucose concentrations compared with Sham
animals and the effect lowering glucose lasted for 6 h, but Reg-
In significantly reduced glucose lasted only for 2 h (Figure 2A).
Insulin pharmaceutical kinetic dynamical results showed that
the insulin concentrations reach to the peak at 15 min of post-
injection for Reg-In and CRI, but insulin levels at 15 and 30 min
of post injection were significantly higher in CRI group than in
Reg-In groups (P < 0.05). The insulin levels at 4 and 6 h after
insulin injection were still significantly higher in CRI but not in
Reg-In than in Sham animals (P < 0.01 and P < 0.05, Figure 2B).
Hepatic insulin signaling protein abundance was measured by
western blotting, the data showed that CRI significantly increased
hepatic IRS-1, IRS-2, PI 3K, and phosphorylation of Akt2 con-
tent in comparison to the Sham group (P < 0.01, P < 0.001, and
P < 0.05; respectively), slightly increased IRS-1 phosphorylation
without affecting IRβ and Akt2 content, while Reg-In only signifi-
cantly increased Akt2, slightly increased IRS-1 and Akt2 p content
in relative to the Sham mice, but did not alter IRS-1 p, IR β, and
PI 3K content (Figure 3).
Chromium–insulin treatment reduced IDE and proteasome
protein abundance in the liver of mice. Interestingly, CRI signifi-
cantly reduced hepatic IDE abundance when compared with the
Sham and Reg-In groups (P < 0.001 and P < 0.01, respectively).
CRI slightly reduced 19S and 20S abundance in relative to Sham
group. However, the 19S and 20S proteins in the liver were sig-
nificantly lower in the CRI than in the Reg-In animals. Reg-In
slightly reduced IDE content and increased 19S proteasome, but
significantly increased 20S proteasome protein abundance when
compared with Sham group (P =NS and P < 0.05, Figure 4). The
effects of CRI on reducing IDE, 19S, and 20S proteasome protein
abundance were further confirmed in HepG2 cells when compared
with Reg-In (Figures S1A,B in Supplementary Material).
DISCUSSION
Our previous study indicates that CrPic supplementation signif-
icantly improves glucose metabolism and increases insulin sen-
sitivity by enhancing insulin signaling in obese insulin-resistant
JCR:LA-cp rats (7). However, CrPic is an oral supplementation.
Using a novel form of insulin conjugated with chromium – CRI
and Reg-In treated KKAy mice, we observed that both insulin treat-
ments significantly reduced glucose concentrations and increased
insulin levels compared with the Sham group, and there was no
difference in glucose levels in 2 h between two insulin groups.
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FIGURE 2 | Effects of Reg-In and CRI on glucose metabolism as well as
their pharmaceutical kinetics dynamics study in KKAy mice. At week 7,
KKAy mice were sub-muscularly injected insulin at dose of 2 U/kg body
weight. Blood samples were collected at various time points as indicated in
the legends. Data were presented as mean±SEM (n=8/group). *P <0.05
and **P < 0.01 and ***Sham vs. Regular-In or CRI. #P <0.05, ##P <0.01
and ###P <0.001, Reg-In vs. CRI vs. Reg-In group.
However, CRI significantly reduced glucose concentrations at 4
and 6 h compared with Sham mice whereas Reg-In did not, sug-
gesting that the effects of CRI on reducing glucose last longer
than Reg-In. Plasma insulin concentrations at 30 and 60 min
were significantly higher in the CRI group than in the Reg-
In group (P < 0.05) as well. Compared with the Sham group,
CRI treatment significantly increased hepatic insulin signaling
such as IRS-1, IRS-2, PI 3K, and phosphorylation of Akt, signif-
icantly reduced IDE protein abundance (P < 0.01, P < 0.05, and
P < 0.001, respectively), but Reg-In only significantly increased
Akt1 (P < 0.05). The effects of CRI significantly reduced IDE con-
tent were confirmed in HepG2 cells. Similar to earlier finding that
a significant reduction in serum triglyceride levels in a group of
NIDDM patients treated with chromium (19), we demonstrated
that CRI treatment significantly decreased plasma triglyceride
concentrations compared with Reg-In and Sham groups without
significantly altering plasma cholesterol levels. Moreover, Reg-In
significantly increased hepatic 20S abundance mice and cultured
cells relative to Sham mice and control cells, CRI greatly reduced
20S and 19S content in the liver of mice and cells in comparison
with Reg-In group. Interestingly, both Reg-In and CRI treatments
did not alter body weight and food intake when compared with
Sham group.
One of the major findings in current study is that we are for the
first time to demonstrate the effects of CRI on reduction of hepatic
FIGURE 3 | Hepatic insulin signaling protein abundance in KKAy mice
treated with or without Reg-In and CRI. Liver lysates were subjected
SDS-PAGE and transferred to nitrocellulose membranes, interesting
proteins of insulin signaling were detected with specific antibodies against
IRS-1, IRS-2, and so on showed in the legends. Results were normalized by
β-actin. Data were presented as mean±SEM (n=8/group). *P <0.05,
**P < 0.01, and ***P <0.001, CRI or Reg-In group vs. Sham group,
respectively. #P <0.05, CRI vs. Reg-In.
IDE protein abundance in a diabetic animal model. Accumulated
evidence indicated that IDE has also been linked to the etiology of
some diseases, such as AD and type 2 diabetes mellitus (DM2) (3),
associating the protein to a wide range of cellular processes, such
as, varicella zoster virus infection, steroid receptor signaling, and
IDE serves as a heat shock protein with implications in cell growth
regulation and cancer progression (13, 20, 21). A consequence of
insulin-dependent diabetes mellitus is the loss of lean muscle mass
as a result of accelerated proteolysis by the proteasome. Insulin
inhibition of proteasomal activity requires interaction with IDE.
Thus, IDE may function as an intracellular mediator for insulin
effects on protein degradation (22). Another study suggested that
a mechanism of proteasome inhibition may be the generation of
inhibitory fragments of insulin, or by displacement of IDE from
the proteasome (23). It is well-documented that biometals, such
as copper, aluminum, and zinc, have an important role in patho-
logical conditions of AD and diabetes mellitus. The metabolic
disorders connected with these biometals lead to some metallosta-
sis alterations in the human body and many studies point at a
high level of interdependence between diabetes and several cations.
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FIGURE 4 | Insulin-degrading enzyme, 19S and 20S proteasome
protein abundance was analyzed in the liver of KKAy mice. Detail was
described in the Section “Materials and Methods.” Results were
normalized by β-actin. Data were presented as mean±SEM (n=8/group).
*P <0.05 and ***P <0.001, CRI or Reg-In group vs. Sham group,
respectively. #P <0.05 and ##P < 0.01, CRI vs. Reg-In, respectively.
Therefore, IDE activity toward Aβ peptides can be modulated by
metal ions (24). The effects of different metal ions on the IDE
proteolytic activity toward insulin as well as a designed peptide
comprising a portion of the insulin B chain (B20–30), which has
a very low affinity for metal ions. The results obtained by differ-
ent experimental techniques clearly show that IDE is irreversibly
inhibited by copper (I) but is still able to process its substrates
when it is bound to copper (II) (25). Indeed, our study revealed
that the benefits of CRI on improving glucose metabolism may
contribute to reduce insulin clearance mediated by significantly
decreasing hepatic IDE content in vivo and in vitro experiments
(Figures 3 and 4), suggesting CRI may directly inhibit IDE as well.
Another finding in this study is that CRI enhanced insulin
signaling by suppressing 20S and 19S protein expression. It is
noteworthy to mention that the 26S proteolytic complex (26S pro-
teasome) is a macromolecular assembly thought to be involved in
ATP- and ubiquitin-dependent protein degradation in the cyto-
plasm of higher eukaryotic cells. This complex is composed of
one 20S cylinder particle, e.g., 20 core particle (CP) and two cap-
shaped 19S particles, e.g., 19S regulatory particle (RP) comprising
a set of polypeptides in the M(r) range of 35,000–110,000 (26–28).
Dysfunctional regulation of signaling pathways downstream of the
insulin receptor plays a pivotal role in the pathogenesis of insulin
resistance and type 2 diabetes. Recent study shows that Cullin-
RING E3 ubiquitin ligase 7 (−/−) mouse embryonic fibroblasts
FIGURE 5 |The possible mechanisms of CRI enhancing insulin action
and insulin signaling were shown in figure. The CRI treatment may
directly suppress IDE and ubiquitin-proteasome system (UPS) in the liver,
and result in reduction of insulin clearance and degradation of proteins
(such as IRS-1 and IRS-2) in the downstream of insulin signaling pathway.
The consequent of CRI treatment enhances insulin signaling, increases
insulin sensitivity, and improves glucose metabolism in insulin-resistant and
diabetic conditions.
displayed enhanced AKT and Erk MAP kinase phosphorylation
upon insulin stimulation. Depletion of CUL7 by RNA interference
in C2C12 myotubes led to increased activation of insulin signaling
pathways and cellular glucose uptake, as well as a reduced capac-
ity of these cells to execute insulin-induced degradation of IRS-1
(29). In this study, we observed that CRI treatment significantly
increased hepatic IRS-1, IRS-2, and PI3K protein abundance as
well as significantly reduced 20S and 19S abundance in diabetic
mice besides inhibition of IDE, indicating that the CRI treatment
enhancing insulin signaling may be contributed to suppressing
ubiquitin-proteasome activity, by which it reduces the degradation
of both insulin and insulin signaling proteins (Figure 5). On the
other hand, it is also interesting to investigate whether CRI is more
effective than Reg-In in treatment of type 1 diabetes in the future.
CONCLUSION
We observed that CRI significantly increased downstream pro-
teins of insulin signaling pathway and decreased hepatic IDE, 19S
and 20S proteasome protein abundance in KKAy mice when com-
pared with Reg-In group. This study suggests that CRI is more
effective than Reg-In in reducing glucose and attenuating insulin
resistance in diabetic animal model. The possible molecular mech-
anism of CRI enhancing insulin action may contribute to reduce
insulin clearance and protein degradation of insulin signaling by
suppressing hepatic IDE and ubiquitin-proteasome pathway.
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